Since high expression of anti-apoptotic BCL-2 family proteins has been widely reported and highly associated with resistance towards chemotherapy and TRAIL in various pediatric cancers such as leukemias, rhabdomyosarcoma, and neuroblastoma [111,112,113,114,115], several approaches have been proposed over the years to inhibit the function these proteins. This evidence concerns the gene BCL2 and neuroblastoma.